| Citation: |
ZHANG Chao, DU Zongli, LI Zhenglan, SUN Yueyuan, XIE Xiaotong, HU Xuebing, CUI Mengmeng. Efficacy of Jiawei Shengxian Decoction combined with conventional treatment in patients with ejection fraction reserved heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 47-50, 67. DOI: 10.7619/jcmp.20215210
|
To observe effect of Jiawei Shengxian Decoction in patients with heart failure with preserved ejection fraction (HFpEF).
A total of 60 HFpEF patients with qideficiency and blood stasis were selected as study objects, and were randomly divided into experimental group and control group, with 30 cases in each group.The control group was given conventional western medicine treatment, and the experimental group was orally administrated with Jiawei Shengxian Decoction on the basis of the control group.The treatment duration was 12 weeks.The scores of TCM symptoms, 6-minute walking test (6MWT) and changes of N-terminal brain natriuretic peptide (NT-ProBNP) were observed before and after treatment in two groups.
Scores of symptoms of chest tightness and panting, edema, palpitation, fatigue and laziness to speak, spontaneous sweating and shortness of breath between experimental group and control group (P < 0.05 or P < 0.01).The total score of TCM symptoms in two groups after treatment was reduced, but the total score of TCM symptoms in the experimental group decreased more significantly (P < 0.01).After treatment, 6MWT of the two groups was significantly increased, and 6MWT of the experimental group was significantly higher than that of the control group (P < 0.05 or P < 0.01).After treatment, NT-ProBNP in two groups was significantly decreased, and the decrease of NT-ProBNP in the experimental group was greater than that in the control group (P < 0.05 or P < 0.01).
Jiawei Shengxian Decoction has better therapeutic effect in HFpEF patients, it can adjust the functions of viscera, qi and blood, effectively improve the clinical symptoms and heart function of patients with HFpEF, and is an effective treatment.
| [1] |
中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
|
| [2] |
陈可冀, 吴宗贵, 朱明军, 等. 慢性心力衰竭中西医结合诊疗专家共识[J]. 中国中西医结合杂志, 2016, 36(2): 133-141. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201602001.htm
|
| [3] |
DUNLAY S M, ROGER V L, REDFIELD M M. Epidemiology of heart failure with preserved ejection fraction[J]. Nat Rev Cardiol, 2017, 14(10): 591-602. doi: 10.1038/nrcardio.2017.65
|
| [4] |
国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南[J]. 中国医学前沿杂志: 电子版, 2016, 8(9): 19-66. https://www.cnki.com.cn/Article/CJFDTOTAL-YXQY201907001.htm
|
| [5] |
王恒和, 程刚, 刘兴磊. 慢性心力衰竭中医辨证分型与患者心功能及生存质量的关系[J]. 山东医药, 2015, 55(34): 52-53. doi: 10.3969/j.issn.1002-266X.2015.34.022
|
| [6] |
叶剑. 中西医结合治疗老年重症心力衰竭的临床疗效及安全性观察[J]. 贵州医药, 2021, 45(5): 786-787. doi: 10.3969/j.issn.1000-744X.2021.05.052
|
| [7] |
郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 68-85.
|
| [8] |
刘蔚, 尉然. 射血分数保留的心力衰竭的诊断和治疗策略[J]. 中国全科医学, 2021, 24(3): 253-258. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202103001.htm
|
| [9] |
张侃迪, 刘东升, 张俊峰. 射血分数保留型心力衰竭的药物治疗进展[J]. 国际心血管病杂志, 2021, 48(1): 5-8. doi: 10.3969/j.issn.1673-6583.2021.01.002
|
| [10] |
严世芸, 沈雁, 符德玉. 中医药论治慢性心功能不全的思考[J]. 江西中医学院学报, 2004, 16(3): 5-6. doi: 10.3969/j.issn.1005-9431.2004.03.001
|
| [11] |
匡朋, 陆露, 韦飞, 等. 三焦论治慢性心力衰竭[J]. 辽宁中医杂志, 2020, 47(3): 73-75. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202003022.htm
|
| [12] |
谈晓双, 文乐兮. 升陷汤的现代文献分析[J]. 中医药导报, 2020, 26(9): 144-147. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZB202009038.htm
|
| [13] |
寇亚强. 升陷汤加味治疗慢性充血性心力衰竭的临床观察[J]. 大家健康: 上旬版, 2017, 11(3): 50-51. https://www.cnki.com.cn/Article/CJFDTOTAL-SCZY200504026.htm
|
| [14] |
李兰波. 升陷汤治疗慢性心力衰竭50例临床观察[J]. 光明中医, 2008, 23(5): 634-635. doi: 10.3969/j.issn.1003-8914.2008.05.051
|
| [15] |
曲艺, 但文超, 刘金垒, 等. 基于网络药理学的升陷汤治疗心力衰竭的作用机制研究[J]. 世界科学技术-中医药现代化, 2020, 22(10): 3583-3593. https://www.cnki.com.cn/Article/CJFDTOTAL-SJKX202010025.htm
|
| [16] |
赵洁, 王欢欢, 欧阳意, 等. 基于网络药理学及质谱技术的葶苈大枣泻肺汤抗心力衰竭的有效成分发现及作用机制分析[J]. 中国实验方剂学杂志, 2021, 27(8): 151-160. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202108022.htm
|
| [17] |
王居平, 杨维伦, 施乐. 中医药治疗慢性心力衰竭的药理机制与研究进展[J]. 实用临床医药杂志, 2020, 24(12): 125-128. doi: 10.7619/jcmp.202012035
|
| [18] |
周喜丹, 唐力英, 周国洪, 等. 南北葶苈子的最新研究进展[J]. 中国中药杂志, 2014, 39(24): 4699-4708. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY201424003.htm
|
| [19] |
刘鹏宇, 贾秀丽. 中医药治疗慢性心力衰竭的研究进展[J]. 湖南中医杂志, 2018, 34(2): 151-154. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZO201802081.htm
|
| [20] |
吕李飞, 吴俊松, 苟江腾, 等. 基于网络药理学及外周血基因芯片技术探究温阳益气活血方治疗慢性心衰的作用机制[J]. 中草药, 2021, 52(18): 5626-5642. doi: 10.7501/j.issn.0253-2670.2021.18.018
|
| [21] |
孙梓宜, 黄力, 廖江铨, 等. 基于网络药理学和分子对接技术预测升解通瘀汤治疗慢性心衰的分子机制[J]. 中国药学杂志, 2021, 56(18): 1486-1495. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYX202118008.htm
|
| [22] |
王艳敏. 葶苈大枣泻肺汤加减联合西医常规治疗心力衰竭临床研究[J]. 新中医, 2021, 53(14): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-REND202114007.htm
|
| [23] |
乔利杰, 李彬, 朱明军, 等. 葶苈大枣泻肺汤加减治疗心力衰竭疗效与安全性的Meta分析[J]. 中西医结合心脑血管病杂志, 2021, 19(3): 365-370. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYY202103003.htm
|
| [24] |
贾彩霞, 陈建新, 高阔, 等. 川芎治疗心力衰竭的网络药理学研究[J]. 世界中医药, 2020, 15(8): 1093-1097. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202008001.htm
|
| [25] |
高涛, 刘伟, 薛一涛. 基于网络药理学探讨复心汤治疗心力衰竭的作用机制[J]. 中华中医药学刊, 2020, 38(2): 37-40, 263. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202002010.htm
|
| [26] |
李雪, 乐暾, 冯彦超, 等. 慢性非传染性疾病管理模式的现状[J]. 中外医学研究, 2021, 19(7): 184-187. https://www.cnki.com.cn/Article/CJFDTOTAL-YJZY202107069.htm
|
| 1. |
宋承骏，毛茅，舒鹏飞，应乐园. 前列地尔联合西洛他唑治疗下肢动脉硬化闭塞症介入术后再狭窄的疗效. 中国药物与临床. 2024(20): 1346-1351 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: